에서 실시간으로 운영 중이에요! 자세히 알아보기

NeoGenomics

NEO

시가총액 US$21.4억

16.65 USD

-0.60

3.48%

장 마감 시점 업데이트됨 10월 16일 PM 4:00 EDT

프리마켓

시간외 거래

16.66

+0.01

0.06%

1일

-3.48%

5일

1.83%

1개월

-12.09%

3개월

12.2%

6개월

104.04%

연초 이후

41.58%

1년

61.96%

5년

-61.86%

10년

121.7%

소개: NeoGenomics Inc provides oncology diagnostic testing and consultative services which include technical laboratory services and professional interpretation of laboratory test results by licensed physicians or molecular experts in pathology and oncology. The company operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. The company operates in a single segment and derives revenue from clients by providing clinical cancer testing, interpretation, and consultative services, molecular and NGS testing, comprehensive technical and professional services offerings, clinical trials and research, validation laboratory services, and oncology data solutions.

직원 수: 2,500

건강관리 진단 및 리서치

뉴스

긍정적

중립

부정적

투자 심리 3개월

긍정적 26.7%

중립 66.7%

부정적 6.7%

NeoGenomics Expands Indica Labs Partnership to Scale AI-Powered Digital Pathology

FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics expanded its partnership with Indica Labs to scale AI-powered digital pathology and support more timely, consistent diagnostic insights.

NeoGenomics Expands Indica Labs Partnership to Scale AI-Powered Digital Pathology

NeoGenomics to Report Third Quarter 2026 Financial Results on October 28, 2026

FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics will report its third quarter 2026 financial results after the close of the U.S. financial markets on Wednesday, October 28, 2026.

NeoGenomics to Report Third Quarter 2026 Financial Results on October 28, 2026

What's Going On With NeoGenomics Stock Tuesday?

Precision medicine and oncology diagnostics provider NeoGenomics Inc. (NASDAQ:NEO) on Monday announced an executive succession plan and preliminary third-quarter financial results for the period ended Sept. 30, 2026.

What's Going On With NeoGenomics Stock Tuesday?

Investors Business Daily

Stryker, Neogenomics Announce CEO Transitions; But One Stock Dives

Stryker and Neogenomics stocks diverged Tuesday after the medtech companies announced their chief executives would soon step down.

Stryker, Neogenomics Announce CEO Transitions; But One Stock Dives

NeoGenomics Announces Executive Leadership and Board of Directors Succession Plan

FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics today announced its executive leadership and board of directors succession plan.

NeoGenomics Announces Executive Leadership and Board of Directors Succession Plan

NeoGenomics Highlights NGS, MRD Growth Strategy at Morgan Stanley Conference

NeoGenomics NASDAQ: NEO executives outlined the company's strategy to expand its role in community-based precision oncology, emphasizing growth in next-generation sequencing, minimal residual disease testing and workflow tools designed for physicians treating patients closer to home.

NeoGenomics Highlights NGS, MRD Growth Strategy at Morgan Stanley Conference

NeoGenomics, Inc. (NEO) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

NeoGenomics, Inc. (NEO) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

NeoGenomics, Inc. (NEO) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

NeoGenomics to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference

FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics will participate in the Morgan Stanley 24th Annual Global Healthcare Conference, Sept. 14–16, 2026, in New York.

NeoGenomics to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference

NeoGenomics Receives Medicare Coverage for RaDaR ST for Immunotherapy Treatment Response Monitoring

FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics announced expanded MolDX coverage for its RaDaR® ST MRD assay for immunotherapy monitoring in late-stage solid tumors.

NeoGenomics Receives Medicare Coverage for RaDaR ST for Immunotherapy Treatment Response Monitoring

Neo Performance Materials Q2 Earnings Call Highlights

Neo Performance Materials TSE: NEO reported record second-quarter results, citing higher volumes, favorable pricing and lower conversion costs across its business segments, while reaffirming expectations to reach the high end of its increased 2026 adjusted EBITDA guidance.

Neo Performance Materials Q2 Earnings Call Highlights

뉴스 순위 보기

Lightweight Charts™를 사용해 가격 차트를 구현했어요.